New rapid tests aim to speed up ebola and lassa fever diagnosis

NCT ID NCT07681752

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study evaluates two new diagnostic tests (FORTIFIEDx and DECIPHER) for detecting Ebola and Lassa viruses. Researchers will use stored blood and cheek swab samples from patients in Guinea to see how well these tests compare to the standard PCR method. The goal is to determine if these faster, simpler tests can accurately identify infections, which could help in future outbreaks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

FORTIFIEDx and DECIPHER bioassays (diagnostic tests using isothermal nucleic acid amplification)

What this could lead to

If accurate, these tests could enable faster, simpler diagnosis of Ebola and Lassa fever in remote areas, improving outbreak response.

What could go wrong

This is a retrospective study using stored samples, not a real-world test. The new tests may not perform as well in field conditions or detect all cases.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBOLA HEMORRHAGIC FEVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ebola hemorrhagic fever Lassa fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••